Horizon Discovery drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine.

With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines

Horizon is headquartered in Cambridge, UK with offices in USA and Japan.

During the conference we'll be presenting posters focused on our new, novel CRISPRi repression system, as well as an approach for multiplexing CRISPRko & CRISPRa, meet Kevin & Clarence during their poster sessions

1. CRISPR-mediated transcriptional repression with a novel dCas9 fusion protein and synthetic guide RNAs

Clarence S Mills, Session 1, Floor 1

2. CRISPR-mediated transcriptional activation and simultaneous gene knockout and activation with synthetic guide RNAs

Kevin Hemphill, Session 1, Floor 3